{"id":627605,"date":"2022-11-28T21:14:01","date_gmt":"2022-11-28T21:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=627605"},"modified":"2022-11-28T21:14:01","modified_gmt":"2022-11-28T21:14:01","slug":"venous-leg-ulcers-market-to-exhibit-substantial-growth-during-the-forecast-period-202232-key-players-ticeba-rheacell-mediwound-reponex-energenesis-solascure-tr-therapeutics-promore","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/venous-leg-ulcers-market-to-exhibit-substantial-growth-during-the-forecast-period-202232-key-players-ticeba-rheacell-mediwound-reponex-energenesis-solascure-tr-therapeutics-promore_627605.html","title":{"rendered":"Venous Leg Ulcers Market to Exhibit Substantial Growth During the Forecast Period (2022-32) | Key Players – TICEBA, RHEACELL, MediWound, Reponex, Energenesis, Solascure, TR Therapeutics, Promore"},"content":{"rendered":"
\n
\"Venous<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Venous Leg Ulcer therapeutics market is anticipated to evolve immensely in the coming years owing to the increase in the number of patients suffering from Venous Leg Ulcer in the 7MM, which would lead to higher adoption of therapeutic drugs.<\/div>\n

DelveInsight’s “Venous Leg Ulcers Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Venous Leg Ulcers market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Venous Leg Ulcers market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Venous<\/p>\n

Venous Leg Ulcers: An Overview<\/strong><\/p>\n

A Venous Leg Ulcers (VLU) is defined as the loss of skin below the knee on the leg or foot in the presence of venous disease. These ulcers persist for more than 6 weeks and are therefore referred to as chronic VLUs, representing the most advanced form of chronic venous disorders like varicose veins and lipodermatosclerosis.<\/p>\n

In patients with venous disease or failure, venous pressure in the deep system falls less than normal during ambulation and rises in an orthostatic position, termed venous hypertension. There is no general consensus about the transition from venous hypertension to venous ulceration.<\/p>\n

Venous Leg Ulcers have a negative impact on the quality of life and result in considerable costs to both patients and healthcare providers. Also, there are no uniform guidelines for assessing and managing this group of conditions, which is reaching epidemic proportions in prevalence.<\/em><\/p>\n

Venous Leg Ulcers Market Key Facts<\/strong><\/p>\n